Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. November 2015 08:00 ET | Quelle: Oryzon

Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001

BARCELONA, Spain and CAMBRIDGE Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...
04. November 2015 08:00 ET | Quelle: Oryzon

ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors

BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...
02. November 2015 08:00 ET | Quelle: Oryzon

Oryzon Announces Oral Presentation on ORY-2001 at 8th Annual Clinical Trials on Alzheimer's Disease Conference

BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...
27. Oktober 2015 08:00 ET | Quelle: Oryzon

ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs

4.9 million new shares issued at a price of 3.39 euros per share The company is valued at $110 million The new shareholders include CEO of Active Motif, a US epigenetics company, also a...

Vorherige Seite